Biotech Adam Feuerstein Sarepta gene therapy for Duchenne muscular dystrophy stumbles with failed study outcome
Biotech Adam Feuerstein New rare disease gene therapy startup recruits former Sarepta executive as CEO
In the Lab Rebecca Robbins Gene therapy pioneer says the field is behind — and that delivery technology is ‘embarrassing’
First Opinion Jeremy Schafer Should employers take a chance on little-known Embarc to pay for gene therapy?
Pharma Adam Feuerstein At $2.1 million, newly approved Novartis gene therapy will be world’s most expensive drug
Biotech Jonathan Saltzman — Boston Globe Affinia Therapeutics raises $110 million for gene therapy treatments
Biotech Adam Feuerstein Bluebird’s withdrawal of therapy from Germany could chill talks over gene therapy prices across Europe
Biotech Adam Feuerstein Uniqure investigation clears hemophilia B gene therapy as cause of patient’s liver cancer
Biotech Adam Feuerstein Bluebird suspends studies of sickle cell gene therapy following cancer diagnoses in two more treated patients
Health Elizabeth Cooney Recapping ASCO 2020, talking cancer therapy combinations, and looking to the future
Pharmalot Ed Silverman Novartis unit says FDA wasn’t told of data manipulation sooner because it was ‘highly complex’
Biotech Jonathan Saltzman — Boston Globe The world’s most expensive medicine could save toddlers’ lives. But getting it is complicated
Biotech Adam Feuerstein Bluebird’s gene therapy for a rare blood disease will cost $1.8 million. Cue the pricing debate
Biotech Adam Feuerstein and Matthew Herper Biomarin to seek approval for hemophilia gene therapy, but durability questions persist
Biotech Jonathan Saltzman — Boston Globe Novartis CEO coy about pricing its gene therapy for spinal muscular atrophy
Biotech Adam Feuerstein Tocagen continues a brain cancer gene therapy clinical trial. Investors fear the worst
Biotech Adam Feuerstein BioMarin’s hemophilia gene therapy faces a crucial durability test. Here are 9 things to know
Biotech Adam Feuerstein With positive early results, Sarepta appears to have a second gene therapy with potential
Biotech Matthew Herper Solid Biosciences to soldier on as initial muscular dystrophy gene therapy results disappoint
Biotech Adam Feuerstein With new data, a biotech tries to relieve doubts about the durability of its gene therapy for Fabry disease
Adam's Take Adam Feuerstein Misfortune strikes a Bluebird patient, highlighting the safety risks involved with gene therapy
Biotech Adam Feuerstein Amicus Therapeutics acquires portfolio of gene therapies targeting neurologic disorders
Adam's Take Adam Feuerstein A gene therapy for overactive bladder? A waste of time and money that trivializes a lifesaving technology
First Opinion Fred D. Ledley 30 years is too long to wait for new medicines. There are ways to speed up drug development
Biotech Ike Swetlitz FDA plans to speed path to approval for some gene therapies, starting with hemophilia
Biotech Eric Boodman ‘That’s $425,000 right there’ — the anxious launch of a gene therapy with a record sticker price
Pharmalot Ed Silverman Pharmalittle: Insulin study causes a big flap; Glaxo gets a reprieve thanks to a Novartis setback